Literature DB >> 7947041

Effect of lidocaine on the hematopoietic properties of recombinant human erythropoietin in the uremic rat.

R A Kaplan1, S Allen, B A Warady, U S Alon.   

Abstract

Subcutaneous injections of recombinant human erythropoietin (rHuEPO) produce considerable pain which can result in noncompliance. As a prelude to an investigation of the possible use of local anesthetics as additives to subcutaneous rHuEPO, we examined the effect of the addition of lidocaine on the erythropoietic properties of rHuEPO. Two weeks after 5/6 nephrectomy, 22 rats were randomly assigned to the following groups: normal saline, rHuEPO, lidocaine, and rHuEPO plus lidocaine. Injections were given three times a week for 2 weeks. No change in hematocrit was observed in the saline and lidocaine groups. The hematocrit of the rHuEPO rats increased from 44.5 +/- 1.4% (mean +/- SD) to 61.6 +/- 2.1% (P < 0.0005), and that of the rHuEPO plus lidocaine group from 42.8 +/- 4.3% to 63.9 +/- 3.0% (P < 0.005), with no difference between the groups. We conclude that the combination of rHuEPO plus lidocaine is as effective as rHuEPO alone in increasing the hematocrit of rats with chronic renal failure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7947041     DOI: 10.1007/bf00856536

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  13 in total

1.  Assessment of pain after subcutaneous injection of erythropoietin in patients receiving haemodialysis.

Authors:  L A Frenken; H J van Lier; P G Gerlag; M den Hartog; R A Koene
Journal:  BMJ       Date:  1991-08-03

2.  Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants.

Authors:  V Carnielli; G Montini; R Da Riol; R Dall'Amico; F Cantarutti
Journal:  J Pediatr       Date:  1992-07       Impact factor: 4.406

3.  Effect of erythropoietin on granulocytopoiesis: in vitro and in vivo studies in weanling rats.

Authors:  J M Koenig; R D Christensen
Journal:  Pediatr Res       Date:  1990-06       Impact factor: 3.756

4.  Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.

Authors:  J W Eschbach; J C Egrie; M R Downing; J K Browne; J W Adamson
Journal:  N Engl J Med       Date:  1987-01-08       Impact factor: 91.245

5.  Identification of the component part in an epoetin alfa preparation that causes pain after subcutaneous injection.

Authors:  L A Frenken; H J van Lier; J G Jordans; K M Leunissen; R van Leusen; V M Verstappen; R A Koene
Journal:  Am J Kidney Dis       Date:  1993-10       Impact factor: 8.860

6.  Recombinant human erythropoietin therapy in pediatric patients receiving long-term peritoneal dialysis.

Authors:  B A Warady; R J Sabath; C A Smith; U Alon; S Hellerstein
Journal:  Pediatr Nephrol       Date:  1991-11       Impact factor: 3.714

7.  Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass.

Authors:  D L Garcia; S Anderson; H G Rennke; B M Brenner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

8.  Administration of erythropoietin to newborn rats results in diminished neutrophil production.

Authors:  R D Christensen; K W Liechty; J M Koenig; K R Schibler; R K Ohls
Journal:  Blood       Date:  1991-09-01       Impact factor: 22.113

9.  Early treatment of premature infants with recombinant human erythropoietin.

Authors:  J Messer; J Haddad; L Donato; D Astruc; J Matis
Journal:  Pediatrics       Date:  1993-10       Impact factor: 7.124

10.  Pain at the injection site of subcutaneously administered erythropoietin in maintenance hemodialysis patients: a comparison of two brands of erythropoietin.

Authors:  N Veys; R Vanholder; N Lameire
Journal:  Am J Nephrol       Date:  1992       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.